Tamoxifen and risk of contralateral breast cancer for \textitBRCA1 and \textitBRCA2 mutation carriers

MLA

Phillips, K. A., et al. Tamoxifen and Risk of Contralateral Breast Cancer for \textitBRCA1 and \textitBRCA2 Mutation Carriers. Jan. 2013. EBSCOhost, https://doi.org/10.1200/JCO.2012.47.8313⟩.

APA

Phillips, K. A., Milne, R. L., Rookus, M. A., Daly, M. B., Antoniou, A. C., Peock, S., Frost, D., Easton, D. F., Ellis, S., Friedlander, M. L., Buys, S. S., Andrieu, N., Nogues, C., Stoppa-Lyonnet, D., Bonadona, V., Pujol, P., McLachlan, S. A., John, E. M., Hooning, M. J., … Hopper, J. L. (2013). Tamoxifen and risk of contralateral breast cancer for \textitBRCA1 and \textitBRCA2 mutation carriers. https://doi.org/10.1200/JCO.2012.47.8313⟩

Chicago

Phillips, K. A., R. L. Milne, M. A. Rookus, M. B. Daly, A. C. Antoniou, S. Peock, D. Frost, et al. 2013. “Tamoxifen and Risk of Contralateral Breast Cancer for \textitBRCA1 and \textitBRCA2 Mutation Carriers,” January. doi:10.1200/JCO.2012.47.8313⟩.